GROSSE POINTE FARMS, Mich., June 4, 2024 /PRNewswire/ -- SciTech Development, a clinical-stage, specialty oncology pharmaceutical company, today announced it has closed an additional $3.2 million in funding to continue the active enrollment and dosing of patients in its ongoing clinical trial for T-cell non-Hodgkin lymphoma (T-NHL).